{
    "2019-03-11": [
        [
            {
                "time": "",
                "original_text": "众生药业“NASH”靶向药获俄罗斯专利证书 股价上涨3.18%",
                "features": {
                    "keywords": [
                        "众生药业",
                        "NASH",
                        "靶向药",
                        "俄罗斯专利",
                        "股价上涨"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药明康德测试事业部通过美国FDA等现场核查",
                "features": {
                    "keywords": [
                        "药明康德",
                        "测试事业部",
                        "FDA",
                        "现场核查"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【华泰医药代雯团队】药明康德(2359 HK)事件点评：合全药业终止挂牌以促进长期发展",
                "features": {
                    "keywords": [
                        "药明康德",
                        "合全药业",
                        "终止挂牌",
                        "长期发展"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "药明康德旗下合全药业摘牌新三板",
                "features": {
                    "keywords": [
                        "药明康德",
                        "合全药业",
                        "摘牌",
                        "新三板"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "[看好评级] 医药政策系列深度之一：医保支付能力不必过于悲观 关注细分板块投资机会",
                "features": {
                    "keywords": [
                        "医药政策",
                        "医保支付",
                        "投资机会",
                        "细分板块"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业:科创板助力,带动医药板块估值回升",
                "features": {
                    "keywords": [
                        "医药生物",
                        "科创板",
                        "估值回升"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}